Forest Laboratories names Alex Kelly Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations

Forest Laboratories, Inc. (NYSE:FRX) today announced that Alex Kelly has been named Senior Vice President, Chief Communications Officer, Public Affairs and Investor Relations. In this role, Alex will lead Forest’s corporate communications and investor relations (IR) programs, including internal and external communications, media relations, corporate branding, product communications, and public affairs. He will serve as top advisor to the Forest leadership team with regard to all matters related to the company’s reputation, messaging, and external communications strategy. Additionally, he will collaborate in the development of corporate strategy and serve as a corporate spokesperson. Kelly will report to Brent Saunders, Chief Executive Officer and President. Frank Murdolo, Vice President Investor Relations, will continue in his role and report directly to Kelly.

“Alex brings to Forest extensive executive experience in global communications and investor relations from a career that spans more than 24 years in the pharmaceutical industry,” said Brent Saunders. “By unifying our communications under Alex, Forest will enhance its engagement with key stakeholders at this important time for the Company.”

Kelly most recently served as Vice President, Investor Relations at Bausch + Lomb after serving as Senior Vice President, Investor Relations at Merck & Co., Inc. Prior to Merck, he led the Global Communications and IR team for Schering-Plough and was responsible for internal and external communications, IR, media relations, product communications, web site and corporate branding. He previously worked for Novartis and Pharmacia, where he spent ten years in pharmaceutical sales and sales management.

Kelly holds a Bachelor of Science in Pharmacy from Purdue University, where he graduated Cum Laude.

About Forest Laboratories

Forest Laboratories' (NYSE: FRX) longstanding global partnerships and track record developing and marketing pharmaceutical products in the United States have yielded its well-established central nervous system and cardiovascular franchises and innovations in anti-infective, respiratory, gastrointestinal and pain management medicine. Forest’s pipeline, the most robust in its history, includes product candidates in all stages of development across a wide range of therapeutic areas. The Company is headquartered in New York, NY. To learn more, visit www.FRX.com.

Except for the historical information contained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any subsequent SEC filings. Forest assumes no obligation to update forward-looking statements contained in this release to reflect new information or future events or developments.

Frank J. MurdoloVice President - Investor Relations, Forest Laboratories, Inc.1-212-224-6714media.relations@frx.com

Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024